Verastem (VSTM) Interest & Investment Income (2012 - 2026)
Verastem's quarterly Interest & Investment Income came in at $1.3 million in Q1 2026, up 35.1% year-on-year from $960000.0 in Q1 2025, and up 17.48% quarter-over-quarter from $1.1 million in Q4 2025.
Verastem has reported Interest & Investment Income for 15 years, with the latest figure at $1.3 million in Q1 2026.
- For the quarter ending Q1 2026, Interest & Investment Income rose 35.1% year-over-year to $1.3 million; the trailing twelve-month figure through Mar 2026 stood at $4.4 million (up 17.72% YoY), and the FY2025 full-year result was $4.1 million, down 1.95% from the prior year.
- Interest & Investment Income for Q1 2026 stood at $1.3 million, up from $1.1 million in the prior quarter.
- The five-year high for Interest & Investment Income was $2.2 million in Q3 2023, with the low at $46000.0 in Q1 2022.
- Average Interest & Investment Income over 5 years is $996647.1, with a median of $976000.0 recorded in 2023.
- Year-over-year, Interest & Investment Income surged 2021.74% in 2023 and slumped 63.02% in 2024.
- Tracing VSTM's Interest & Investment Income over 5 years: stood at $769000.0 in 2022, then surged by 143.04% to $1.9 million in 2023, then sank by 48.21% to $968000.0 in 2024, then climbed by 14.05% to $1.1 million in 2025, then advanced by 17.48% to $1.3 million in 2026.
- The last three Interest & Investment Income figures came in at $1.3 million (Q1 2026), $1.1 million (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 7.90 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 114.80 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 305,000.00 |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 26.60 Mn |
| 10 | Verastem | 425.60 Mn | 243.93 Mn | 15.90 Mn | 1.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.30 Mn |
| Dec 31, 2025 | 1.10 Mn |
| Sep 30, 2025 | 1.18 Mn |
| Jun 30, 2025 | 822,000.00 |
| Mar 31, 2025 | 960,000.00 |
| Dec 31, 2024 | 968,000.00 |
| Sep 30, 2024 | 831,000.00 |
| Jun 30, 2024 | 983,000.00 |
| Mar 31, 2024 | 1.37 Mn |
| Dec 31, 2023 | 1.87 Mn |
| Sep 30, 2023 | 2.25 Mn |
| Jun 30, 2023 | 1.12 Mn |
| Mar 31, 2023 | 976,000.00 |
| Dec 31, 2022 | 769,000.00 |
| Sep 30, 2022 | 316,000.00 |
| Jun 30, 2022 | 84,000.00 |
| Mar 31, 2022 | 46,000.00 |
| Dec 31, 2021 | 40,000.00 |
| Sep 30, 2021 | 40,000.00 |
| Jun 30, 2021 | 49,000.00 |
| Mar 31, 2021 | 52,000.00 |
| Dec 31, 2020 | 18,000.00 |
| Sep 30, 2020 | 19,000.00 |
| Jun 30, 2020 | 122,000.00 |
| Mar 31, 2020 | 356,000.00 |
| Dec 31, 2019 | 611,000.00 |
| Sep 30, 2019 | 1.01 Mn |
| Jun 30, 2019 | 1.27 Mn |
| Mar 31, 2019 | 1.50 Mn |
| Dec 31, 2018 | 1.31 Mn |
| Sep 30, 2018 | 763,000.00 |
| Jun 30, 2018 | 343,000.00 |
| Mar 31, 2018 | 191,000.00 |
| Dec 31, 2017 | 145,000.00 |
| Sep 30, 2017 | 121,000.00 |
| Jun 30, 2017 | 140,000.00 |
| Mar 31, 2017 | 155,000.00 |
| Dec 31, 2016 | 145,000.00 |
| Sep 30, 2016 | 137,000.00 |
| Jun 30, 2016 | 140,000.00 |
| Mar 31, 2016 | 140,000.00 |
| Dec 31, 2015 | 98,000.00 |
| Sep 30, 2015 | 89,000.00 |
| Jun 30, 2015 | 85,000.00 |
| Mar 31, 2015 | 62,000.00 |
| Dec 31, 2014 | 49,000.00 |
| Sep 30, 2014 | 56,000.00 |
| Jun 30, 2014 | 65,000.00 |
| Mar 31, 2014 | 72,000.00 |
| Dec 31, 2013 | 69,000.00 |
| Sep 30, 2013 | 53,000.00 |
| Jun 30, 2013 | 34,000.00 |
| Mar 31, 2013 | 44,000.00 |
| Dec 31, 2012 | 55,000.00 |
| Sep 30, 2012 | 63,000.00 |
| Jun 30, 2012 | 71,000.00 |
| Mar 31, 2012 | 57,000.00 |